Searching News Database: FRAME study
HSMN NewsFeed - 13 Jul 2018
Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY(TM) (romosozumab) To The US FDA
Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY(TM) (romosozumab) To The US FDA
HSMN NewsFeed - 17 Jul 2017
Amgen And UCB Provide Update On Regulatory Status Of EVENITY(TM) (romosozumab) In The US
Amgen And UCB Provide Update On Regulatory Status Of EVENITY(TM) (romosozumab) In The US
HSMN NewsFeed - 22 Jul 2016
Amgen and UCB Submit Biologics License Application for Romosozumab to the FDA
Amgen and UCB Submit Biologics License Application for Romosozumab to the FDA
